RPAM
MNTA

Rhenman & Partners Asset Management’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Rhenman & Partners Asset Management’s Portfolio MNTA Stock Details MNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-120,000
Closed -$3.99M – 95
2020
Q2 		$3.99M Sell
120,000
-1,400
-1% -$44.6K 0.43% 71
2020
Q1 		$3.3M Sell
121,400
-56,673
-32% -$1.58M 0.46% 61
2019
Q4 		$3.51M Buy
+178,073
New +$2.85M 0.39% 72

Other funds holding MNTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return

Rhenman & Partners Asset Management's MNTA Position: Q3 2020 in Review

Rhenman & Partners Asset Management sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q3 2020, closing a stake of 120,000 shares — an estimated $3.99M sold.

Rhenman & Partners Asset Management first reported a position in MNTA in Q4 2019 and held it in 3 quarters. The position peaked at $3.99M in Q2 2020. 211 funds tracked by Wall St. Rank hold MNTA as of Q3 2020.

  • Rhenman & Partners Asset Management reported no remaining Momenta Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
  • Rhenman & Partners Asset Management sold 120,000 Momenta Pharmaceuticals, Inc. shares in Q3 2020, an estimated $3.99M.
  • Rhenman & Partners Asset Management first reported a position in Momenta Pharmaceuticals, Inc. in Q4 2019 and held it in 3 quarters.
  • Rhenman & Partners Asset Management's Momenta Pharmaceuticals, Inc. position peaked at $3.99M in Q2 2020.
  • 211 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q3 2020.

Based on Rhenman & Partners Asset Management's 13F filing for Q3 2020, filed 13 Oct 2020.